HCA International Limited Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2009
NCT00973999
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

rimabotulinumtoxinB (Myobloc) (1 trial)

Drugs in Phase 1 Trials (1)

Inactivated Mycobacterium obuense (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Injuries (Phase 2)

Brain Injuries, Traumatic (Phase 2)

Melanoma (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2